translated from Spanish: Johnson & Johnson: U.S. authorities allow vaccine use to resume

U.S. health authorities gave go-ahead this Friday to resume use of Johnson & Johnson (J&J) Janssen covid-19 vaccine, but called for recipients to be nodded on the possibility of extremely rare blood clots forming.

The Centers for Disease Control and Prevention (CDC) previously said in a statement that “the use of the vaccine should be resumed in the United States” and that they “trust that this vaccine is safe and effective in preventing covid-19.”

They added that “thrombus or blood clots are very rare”.

Medical staff and dose recipients “should review the vaccine fact sheet […], which includes information on the risk of this syndrome [de formación de coágulos], which has occurred in a very small number of people who have received it.”

The U.S. stopped using single-dose injection in mid-April due to some reports of blood clotting in the brain among women after receiving the vaccine.

In that country, 15 receptortos of the dose Sufferederonof dangerouss clots blood, of the nearly eight million that had been injected since regulators approved the vaccine in February.

They were all women, most under the age of 50. Three died and seven remain in the hospital.

warning

U.S. health authorities said Friday that it was important for women to be informed of the potential risks of the vaccine so they could decide whether to look for alternatives.

Dr. Sarah Long, of Drexel University School of Medicine in Philadelphia, was among the members of the CDC panel who voted against resuming the use of the J&J vaccine because she believes that women are not sufficiently warned of the risks.

“This is an age group that is at greater risk [de sufrir coágulos de sangre] you’re getting the vaccine predominantly to save other people’s lives and morbidity, not your own,” he said. “And I think we have a responsibility to make sure they know.”

This week, health authorities in Europe also Raised restrictions onLtovaccine by J&J.

European regulators had also linked similar and very unusual blood clots to the AstraZeneca vaccine, but similarly concluded that the benefits of the injection outweighed any risk.

Original source in Spanish